The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
RESPONSE: Re: Relationship Between p53 Mutations and Inducible Nitric Oxide Synthase Expression in Human Colorectal Cancer
Abstract
Cellular expression of inducible nitric oxide synthase, also called NOS2, has recently been shown in various types of human cancer ( 1 - 4 ). NOS2 was mainly found in tumor-infiltrating monocytes and endothelial cells of breast, gastric, and colon tumors ( 1 , 2 ) but was most commonly detected in the epithelium of esophageal ( 3 ) and head and neck ( 4 ) carcinomas. Thus, tumor-associated nitric oxide production may contribute to the pathogenesis of human cancers by various mechanisms. We recently reported that expression of NOS2 might cause specific p53 mutations in human colon tumors, i.e., C to T transitions at CpG sites, and a decreased frequency of other mutations ( 1 ). In this issue, Gallo and co-workers report a statistically significant correlation between the expression of NOS2 and the presence of mutated p53 in tumor cells of head and neck cancer when compared with tumors with wild-type p53. Moreover, the combination of both NOS2 and mutated p53 correlated stronger with an increased vessel density of the tumor than the combination of NOS2 and wild-type p53. Similar findings were made in a xenograft model by the use of human cancer cells that had either wild-type or mutant p53 and expressed constitutively a NOS2 transgene ( 5 ). The authors also confirmed previous data ( 4 ) that revealed a strong positive correlation between the expression of nitric oxide synthase and tumor angiogenesis and tumor progression. A cellular colocalization of NOS2 and mutated p53 was not observed in colon tumors. NOS2 was found to be highest in adenomas. Because p53 mutations mainly arise at the transition from adenoma to carcinoma in situ, we hypothesized that the strong association of NOS2 with the frequency of G : C to A : T mutations at the CpG dinucleotide sequence in carcinomas is the result of NO-induced mutagenesis. Although the results of Gallo and co-workers are solely based on correlations, the data indicate that mutated p53 may permit cancer cells in head and neck cancer to express higher levels of NOS2 when compared with wild-type p53 cancer cells. While this is the conclusion of Gallo and co-workers, we cannot exclude the hypothesis that p53 mutations coincide with NOS2 because the mutations have been caused by nitric oxide released from NOS2. The determination of NOS2 expression levels at different stages of head and neck cancer should provide more clues about which event is first, a mutated p53 or NOS2, since the frequency of p53 mutations increases with the progression of head and neck cancers ( 6 ). If the hypothesis is correct, NOS2 activity should also increase with the progression of head and neck cancer. Nevertheless, the findings of Gallo and co-workers are of interest because they implicate the combination of mutated p53 and NOS2 with tumor progression. In support of the author's hypothesis is a recent investigation that compared NOS2 expression in p53 knockout mice with the expression in the wild-type p53 counterpart ( 7 ). Extending our earlier in vitro studies, we found that wild-type p53 transcriptionally represses C. parvum -induced NOS2 expression, thus supporting the existence of a negative feedback loop between NOS2 and wild-type p53. We also detected increased basal levels of NOS2 in the spleen of p53 knockout animals but not in the liver. It remains unclear whether basal NOS2 expression in the spleen of the p53 knockout mice is the result of an endogenous immunologic stimulus. A p53 mutation may not lead to a spontaneous increase of NOS2 but may permit a higher cytokine-induced NOS2 expression. The effect of a p53 mutation on NOS2 expression levels may also be cell type specific. In fact, when we studied basal NOS2 expression in more than 40 human cancer cell lines either with wild-type or mutant p53, NOS2 expression was found in only two cell lines, SW480 and DLD-1, that both have a mutant p53, but most of the cell lines with mutant p53 did not express NOS2. Therefore, the interrelationship between NOS2 and p53 is an active area of investigation in the field of carcinogenesis, which may have implications in cancer prevention and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Self-citationAmbs, S., Bennett, W. P., Merriam, W. G., Ogunfusika, M. O., Oser, S. M., Harrington, A. M., Shields, P. G., Felley-Bosco, E., Hussain, S. P., & Harris, C. C. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.86 · Cited by 166
Self-citation
Cited by
Marnett, L. J. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.361 · Cited by 1,883
Hussain, S. P., Hofseth, L. J., & Harris, C. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1046 · Cited by 1,690
Self-citationSharma, R. A., Gescher, A. J., & Steward, W. P. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.05.009 · Cited by 1,658
Endogenous DNA damage in humans: a review of quantitative data
De Bont, R. (2004) · Mutagenesis · doi:10.1093/mutage/geh025 · Cited by 1,058
Hussain, S. P., Schwank, J., Staib, F., Wang, X. W., & Harris, C. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210279 · Cited by 621
Self-citation
Metadata
- Authors
- Ambs, S., & Harris, C. C.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-09-01
- Volume
- 91
- Issue
- 17
- Pages
- 1510-1511
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2123082423
- Cited by
- 170
- References
- 2
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RESPONSE: Re: Relationship Between p53 Mutations and Inducible Nitric Oxide Synthase Expression in Human Colorectal Cancer. https://app.cochat.ai/papers/10.1093/jnci/91.17.1510
- The paper
- Ambs, S., & Harris, C. C. (1999). RESPONSE: Re: Relationship Between p53 Mutations and Inducible Nitric Oxide Synthase Expression in Human Colorectal Cancer. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/91.17.1510
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.